tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors

Biogen’s New Study on MS Drug Vumerity: Key Insights for Investors

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.

Elevate Your Investing Strategy:

Biogen Inc. (BIIB) is currently recruiting for a clinical study titled Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry. The study aims to assess the risk of major congenital malformations in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) during pregnancy. It also compares these outcomes with those in women with MS exposed to other disease-modifying therapies (DMTs) and those unexposed to DMTs.

The intervention being tested is Diroximel Fumarate, a drug intended to manage MS symptoms. The study also includes comparisons with other DMTs such as Avonex and Tysabri, as well as a cohort of women without MS.

This observational study follows a cohort model with a prospective time perspective, aiming to gather data over a 52-week period. The primary purpose is to observe and compare pregnancy outcomes across different exposure groups.

The study began on October 27, 2023, with its primary completion date yet to be determined. The latest update was submitted on July 16, 2025, indicating ongoing progress in data collection and analysis.

This study’s findings could significantly impact Biogen’s stock performance by influencing investor sentiment regarding the safety and efficacy of Vumerity. Given the competitive landscape of MS treatments, positive results could enhance Biogen’s market position against other DMT providers.

The study is ongoing, and further details are available on the ClinicalTrials portal.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1